Lantern Pharma to Report Fourth Quarter and Fiscal Year 2025 Operating & Financial Results on March 30th, 2026 at 4:30 p.m. ET To register for the webinar, please sign up at the Zoom webcast link provided in the link: Lantern Pharma Q4 2025 earnings Zoom webcast registration link. A replay of the earnings call webcast will be available after the call on the investor relations section of the Company's website: ir.lanternpharma.com. Share Webcast to be held Monday, March 30th, 4:30 p.m. ET, register for the w ...

Core Insights - New to The Street is a prominent financial media brand that broadcasts weekly on Bloomberg Television and Fox Business, reaching millions of households across the U.S., Latin America, and MENA regions [6] Group 1: Featured Companies - FreeCast (NASDAQ:CAST) is transforming digital media aggregation and streaming access for consumers worldwide [3] - KLED.ai is advancing AI-driven enterprise and data intelligence solutions [3] - Lantern Pharma (NASDAQ:LTRN) is a leader in AI-powered oncology drug development [3] - BlackBarn Restaurant is a premier culinary destination in New York City known for its farm-to-table excellence [3] - Virtuix (NASDAQ:VRTX) specializes in immersive virtual reality technology [4] - NRx Pharmaceuticals (NASDAQ:NRXP) focuses on advanced therapeutics for critical conditions [4] - PetVivo Holdings is involved in veterinary regenerative medicine [4] - DataVault AI (NASDAQ:DVLT) provides data monetization and tokenization infrastructure [4] - Roadzen (NASDAQ:RDZN) offers an AI-powered insurance and mobility platform [4] - Stardust Power (NASDAQ:SDST) is engaged in lithium and energy infrastructure solutions [4] - CISO Global (NASDAQ:CISO) is an enterprise cybersecurity leader [4] - The Sustainable Green Team (OTC:SGTM) focuses on climate and sustainable infrastructure solutions [4] Group 2: Media Reach and Impact - New to The Street has a combined platform reach exceeding 5.1 million subscribers, including 4.44 million on its YouTube channel and over 700,000 on the NewsOut Digital Network [4][5] - The platform utilizes various distribution channels, including LinkedIn, X, Instagram, and Facebook, along with iconic billboard placements in Times Square and NYC's Financial District [4] - New to The Street continues to outperform traditional financial media platforms in terms of reach, engagement, and measurable impact, establishing itself as a dominant force in next-generation financial media [5]

Lantern Pharma Conference Summary Company Overview - **Company**: Lantern Pharma (NasdaqCM: LTRN) - **Industry**: Biotechnology, specifically focused on oncology and AI-driven drug development Key Points and Arguments AI Utilization in Drug Development - Lantern Pharma is leveraging AI through its platform, RADR, to develop new cancer medicines, significantly reducing the time to bring drugs to clinical trials by 70%-80% [5][6] - The company has dosed over 100 patients in clinical trials with drugs developed using its AI platform [5] - AI is used to identify biomarkers that predict patient responses, increasing the likelihood of clinical trial success and reducing trial costs by 30%-50% [6][7] Clinical Trials and Drug Pipeline - Lantern has launched over 10 programs in the last two years, with several in phase one and phase two trials [7] - The company has received fast track designations for multiple drugs, including those targeting triple-negative breast cancer (TNBC) and brain cancers [10][11] - A new subsidiary, Starlight Therapeutics, has been created to focus on brain cancer treatments, with plans for future financing [11][26] Market Potential and Financials - The market opportunity for the drug LP-184 is estimated to exceed $10 billion [24] - Lantern has 12 FDA designations, including 2 fast track and 6 orphan designations, highlighting its strong regulatory position [18] - The company reported a capital of approximately $12 million with a burn rate of $4 million per quarter, providing sufficient runway into Q3 [27][28] AI Platform and Future Developments - The AI platform has processed approximately 500 billion data points, utilizing hundreds of algorithms for drug development [12] - Lantern is developing a subscription-based model for its AI platform, with the potential to monetize its capabilities for drug developers [15][29] - The company aims to position its AI platform as a leading tool in rare cancer research, with plans for further enhancements and public availability [15][37] Competitive Advantage - Lantern Pharma emphasizes its unique position in the market, claiming no other company of its size has achieved as many FDA designations or is conducting multiple trials simultaneously [39] - The RADR platform is publicly available under the name withZeta.ai, which has received positive feedback from early users, including major cancer institutions and pharmaceutical companies [40] Upcoming Milestones - Key catalysts for the upcoming year include data releases for LP-300 and LP-184, as well as the launch of Starlight Therapeutics [36] - The company anticipates significant developments in its AI platform, which could lead to further licensing opportunities with larger pharmaceutical companies [37] Additional Important Information - Lantern Pharma's approach combines drug development with AI capabilities, aiming to streamline processes and enhance the efficiency of clinical trials [20][21] - The company has established collaborations with various research institutions, enhancing its credibility and data access [16][17] - The focus on rare cancers and the development of innovative drugs positions Lantern Pharma as a potentially disruptive player in the biotechnology sector [16][26]

Lantern Pharma, Inc. (NASDAQ:LTRN) is one of the best AI penny stocks to buy right now. On January 20, the FDA granted Lantern Pharma, Inc.’s (NASDAQ:LTRN) LP-284 an Orphan Drug Designation (ODD). LP-284 is an investigational small-molecule therapy for treating soft tissue sarcomas. Lantern Pharma (LTRN) Advances Oncology AI and Gains Orphan Drug Recognition According to Lantern Pharma, the ODD designation applies in the United States under the FDA’s orphan drug program. The program supports the developm ...

Core Insights - Lantern Pharma Inc. will present at the 7th Glioblastoma Drug Development Summit in Boston from February 17-19, 2026, focusing on its AI-driven oncology drug development [1] - The company’s RADR® platform has facilitated the development of LP-184 / STAR-001, a novel therapeutic candidate for CNS cancers, including recurrent glioblastoma and pediatric brain tumors [1] - STAR-001 has received both FDA Orphan Drug Designation and Rare Pediatric Disease Designation, highlighting its potential in treating rare conditions [1] Company Overview - Lantern Pharma is a clinical-stage biopharmaceutical company utilizing artificial intelligence and machine learning to enhance oncology drug discovery and development [1] - The RADR® AI platform integrates hundreds of billions of data points to identify biomarkers, predict drug responses, and design more effective clinical trials [1] - The company’s pipeline includes LP-184, LP-284, and LP-300, each targeting genomically defined patient populations [1] Presentation Highlights - CEO Panna Sharma will discuss the application of RADR® in discovering novel combination therapies, selecting optimal cancer indications, identifying patient biomarkers, and elucidating the mechanism of action of STAR-001 during the summit [1] - The presentation will emphasize AI-driven insights that address challenges in treating aggressive brain cancers like glioblastoma and atypical teratoid/rhabdoid tumors (ATRT) [1]

Core Insights - Lantern Pharma Inc. has reported positive results from its Phase 1a dose-escalation study of LP-184, demonstrating durable disease control in patients with advanced solid tumors, particularly those with DNA damage repair (DDR) pathway deficiencies [1][2] - The company is advancing a precision oncology strategy with multiple biomarker-guided Phase 1b/2 clinical trials targeting triple-negative breast cancer (TNBC), glioblastoma multiforme (GBM), non-small cell lung cancer (NSCLC), and advanced urothelial carcinoma, with an estimated market opportunity exceeding $10 billion annually [1][2] Phase 1a Clinical Trial Results - The Phase 1a trial enrolled 63 heavily pre-treated patients, achieving a 54% disease control rate at therapeutic dose levels, indicating promising activity in DDR-deficient cancers [1][2] - The recommended Phase 2 dose (RP2D) was established at 0.39 mg/kg, with a favorable safety profile characterized by manageable adverse events [1][2] - Over 87% of patients exceeded the PTGR1 bioactivation threshold, validating the biomarker's utility for patient selection [1][2] Patient Durability and Efficacy - Notable patient cases included individuals with stage 4 cancers who have shown ongoing clinical benefits for over 12 to 23 months after treatment with LP-184, highlighting its potential in difficult-to-treat cancers [1][2] - The drug demonstrated activity in both homologous recombination (HR)-deficient and nucleotide excision repair (NER)-deficient tumors, suggesting a broader patient applicability compared to existing therapies [2] Regulatory Support and Designations - LP-184 has received multiple FDA designations, including Fast Track and Orphan Drug designations for various cancers, which facilitate accelerated development and potential expedited approval pathways [2][3] - These designations enhance the company's ability to interact with the FDA and may allow for rolling submissions of New Drug Application (NDA) sections [2] Future Development Plans - Lantern Pharma is planning multiple biomarker-guided Phase 1b/2 trials, including combinations with other therapies for TNBC, NSCLC, and GBM, targeting high unmet medical needs [2][3] - The company is also exploring additional indications, such as post-radiation pancreatic cancer, which may benefit from enhanced PTGR1 expression due to prior treatments [2][3] Company Overview - Lantern Pharma is a clinical-stage biotechnology company focused on using artificial intelligence and genomic data to develop precision oncology therapies [3] - The company's RADR® AI platform integrates extensive data to identify biomarkers and predict drug responses, streamlining the drug development process [3]

Core Insights - Palantir Technologies (NASDAQ: PLTR) has established itself as a leader in AI-driven data analytics, securing significant government contracts and expanding its intelligence business, resulting in a 105% stock price increase year-to-date, trading at $154 [1][2] Company Summaries BigBear.ai (NYSE: BBAI) - BigBear.ai is undergoing a strategic pivot, highlighted by its acquisition of Ask Sage, a generative AI platform for secure sectors like defense, which is expected to generate approximately $25 million in annual recurring revenue in 2025 [3][5] - The acquisition positions BigBear to transition from a decision-intelligence contractor to a full-stack generative AI provider, enhancing its offerings for government clients [4] - With over $450 million in cash, BigBear has the financial flexibility to support growth initiatives and strategic investments, potentially allowing it to carve out a unique position in the defense AI sector [5][6] Lantern Pharma (NASDAQ: LTRN) - Lantern Pharma utilizes its RADR AI platform to innovate oncology drug development, leveraging over 200 billion data points and 200 machine-learning algorithms [7] - The company has shown promising clinical results, with a 48% clinical benefit rate in its LP-184 Phase 1a trial among heavily pretreated patients [8][9] - Lantern is managing its cash effectively, with $19.7 million available, and plans to commercialize parts of its RADR platform, which could generate revenue through licensing [9]

Core Insights - The webinar focuses on the clinical trial results of LP-184, a drug aimed at treating advanced solid tumors [1][2] - Key participants include the CEO, Chief Scientific Officer, Head of Clinical Development, and a collaborator from Fox Chase [2] - The discussion will cover the scientific background, early development, and clinical results of LP-184 [1][3] Company Overview - LP-184 is primarily targeted for the treatment of advanced solid tumors, particularly those that are deficient in certain characteristics [3] Clinical Development - The presentation will delve into the early development of LP-184 and its scientific basis [1][2] - A Q&A session is planned to address audience inquiries regarding the trial and the drug [2]

Lantern Pharma (NasdaqCM:LTRN) Update Summary Company Overview - **Company**: Lantern Pharma - **Drug**: LP-184 - **Focus**: Treatment of advanced solid tumors, particularly those with DNA damage repair deficiencies Key Points Industry and Drug Development - LP-184 is primarily aimed at treating advanced solid tumors, including triple-negative breast cancer (TNBC), glioblastoma (GBM), and bladder cancer, which often exhibit deficiencies in DNA damage repair pathways [2][3] - The drug has completed Phase IA trials with promising safety and tolerability data, showing significant clinical activity across various solid tumor types [3][25] - Lantern Pharma has received three orphan drug designations and two fast-track designations for LP-184, indicating strong market potential [3] Mechanism of Action - LP-184 is designed to exploit synthetic lethality, particularly in tumors with high levels of PTGR1, a gene that enhances the drug's efficacy [4][10] - The drug works by causing double-stranded breaks in DNA, which are particularly lethal to tumor cells deficient in DNA repair mechanisms [4][18] - Tumors with mutations in nucleotide excision repair and homologous recombination pathways show heightened sensitivity to LP-184 [13][14] Clinical Trial Results - The Phase IA study demonstrated a favorable safety profile, with most adverse events being grade 1 or 2 and manageable [31] - Out of 63 enrolled patients, 52 were available for tumor response assessment, with 28 patients achieving stable disease, including four with durable responses lasting over six months [34] - Notably, 87.5% of patients had PTGR1 expression levels sufficient for LP-184 activation, supporting the drug's precision medicine approach [41] Future Clinical Development - Planned Phase IB and II trials will focus on advanced monotherapy and combination therapies, particularly in TNBC and non-small cell lung cancer [26][42] - The trials will utilize a Bayesian adaptive design to expedite the process and improve patient outcomes [28] - There is a strong emphasis on biomarker-driven studies to identify patients most likely to benefit from LP-184 [46] Market Potential - The market for LP-184 is considered exceptional, with estimates suggesting that about 20% of cancers harbor DNA damage repair deficiencies, making them potential candidates for treatment [3][4] - The drug's ability to combine with other therapies, such as PARP inhibitors, positions it as a strong contender in the oncology market [54][55] Additional Insights - LP-184 has shown potential in overcoming resistance to existing therapies, including PARP inhibitors, and may also convert "cold" tumors to "hot" tumors for immunotherapy [15][54] - The drug's ability to cross the blood-brain barrier is particularly advantageous for treating brain metastases associated with TNBC [57] Conclusion - Lantern Pharma's LP-184 represents a promising advancement in the treatment of solid tumors with DNA repair deficiencies, supported by strong preclinical and early clinical data. The ongoing trials and strategic focus on precision medicine could significantly impact patient outcomes and market positioning in oncology [60]

Group 1 - The article does not provide any specific content or key points related to a company or industry [1]